title: Amplicon-dependent CCNE1 expression is critical for clonogenic survival after cisplatin treatment and is correlated with 20q11 gain in ovarian cancer.
abstract: Genomic amplification of 19q12 occurs in several cancer types including ovarian cancer where it is associated with primary treatment failure. We systematically attenuated expression of genes within the minimally defined 19q12 region in ovarian cell lines using short-interfering RNAs (siRNA) to identify driver oncogene(s) within the amplicon. Knockdown of CCNE1 resulted in G1/S phase arrest, reduced cell viability and apoptosis only in amplification-carrying cells. Although CCNE1 knockdown increased cisplatin resistance in short-term assays, clonogenic survival was inhibited after treatment. Gain of 20q11 was highly correlated with 19q12 amplification and spanned a 2.5 Mb region including TPX2, a centromeric protein required for mitotic spindle function. Expression of TPX2 was highly correlated with gene amplification and with CCNE1 expression in primary tumors. siRNA inhibition of TPX2 reduced cell viability but this effect was not amplicon-dependent. These findings demonstrate that CCNE1 is a key driver in the 19q12 amplicon required for survival and clonogenicity in cells with locus amplification. Co-amplification at 19q12 and 20q11 implies the presence of a cooperative mutational network. These observations have implications for the application of targeted therapies in CCNE1 dependent ovarian cancers.
authors.affiliation: Cancer Genomics Program, Peter MacCallum Cancer Centre, East Melbourne, Australia.
authors.forename: Dariush
authors.initials: D
authors.lastname: Etemadmoghadam
authors.forename: Joshy
authors.initials: J
authors.lastname: George
authors.forename: Prue A
authors.initials: PA
authors.lastname: Cowin
authors.forename: Carleen
authors.initials: C
authors.lastname: Cullinane
authors.forename: Maya
authors.initials: M
authors.lastname: Kansara
authors.forename: Kylie L
authors.initials: KL
authors.lastname: Gorringe
authors.forename: Gordon K
authors.initials: GK
authors.lastname: Smyth
authors.forename: David D L
authors.initials: DD
authors.lastname: Bowtell
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology; D015153:Blotting, Western; D002453:Cell Cycle / Q000187:drug effects / Q000235:genetics; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects / Q000235:genetics; D002869:Chromosome Aberrations; D002888:Chromosomes, Human, Pair 19 / Q000235:genetics; D002890:Chromosomes, Human, Pair 20 / Q000235:genetics*; D002945:Cisplatin / Q000494:pharmacology*; D019927:Cyclin E / Q000235:genetics* / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D005260:Female; D005784:Gene Amplification; D006801:Humans; D015513:Oncogene Proteins / Q000235:genetics* / Q000378:metabolism; D010051:Ovarian Neoplasms / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D034622:RNA Interference; D020133:Reverse Transcriptase Polymerase Chain Reaction
chemical_list: D000970:Antineoplastic Agents; C475820:CCNE1 protein, human; D019927:Cyclin E; D015513:Oncogene Proteins; D002945:Cisplatin